Trials / Completed
CompletedNCT00449046
Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-
Clinical Assessment of GW815SF Salmeterol/Fluticasone Propionate (HFA MDI) in Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 5 Years – 14 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the long-term (24-week) safety and efficacy of GW815SF Salmeterol/fluticasone propionate(HFA MDI) 50/100mcg(administered as 2 inhalations of 25/50mcg) bid in pediatric patients with bronchial asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW815SF Salmeterol/Fluticasone propionate(HFA MDI) |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2007-11-01
- Completion
- 2007-11-01
- First posted
- 2007-03-19
- Last updated
- 2015-05-06
- Results posted
- 2009-08-04
Locations
3 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00449046. Inclusion in this directory is not an endorsement.